The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
The company is developing a blood-based liquid biopsy test based on the method to monitor 5-hydroxymethylcytosine levels in cell-free tumor DNA.
The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.
The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
Of the six kits, the team found that Qiagen and Norgen's spin column tools recovered the highest amount of DNA across a range of base pair lengths.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.